Your session is about to expire
← Back to Search
PI3K Inhibitor
Duvelisib for COVID-19
Phase 2
Waitlist Available
Led By John DiPersio, M.D., Ph.D.
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
as a positive test for SARS-CoV-2 RNA detected by RT-PCR collected from the upper respiratory tract (e.g. nasopharyngeal, nasal, oropharyngeal swab, or saliva) and, if possible, the lower respiratory tract (sputum, tracheal aspirate, or bronchoalveolar lavage), analyzed by a CLIA certified lab with an FDA approved assay.
Chest imaging with ≥ 50% lung involvement
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through 29 days
Awards & highlights
Study Summary
This trial is testing if a new drug could help people with severe or critical COVID-19. The drug is designed to reduce inflammation and help the body fight the virus.
Eligible Conditions
- COVID-19
- Coronavirus
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through 29 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through 29 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Overall Survival as Measured by Number of Participants Alive Through 28 Days
Secondary outcome measures
Duration of Vasopressors Use
Duration of Ventilator Use
Duration on Renal Replacement Therapy
+4 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: DuvelisibExperimental Treatment2 Interventions
-Duvelisib 25 mg twice daily for up to 10 days.
Group II: PlaceboPlacebo Group2 Interventions
-Placebo 25 mg twice daily for up to 10 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Duvelisib
2016
Completed Phase 3
~750
Peripheral blood draw
2017
Completed Phase 2
~60
Find a Location
Who is running the clinical trial?
Washington University School of MedicineLead Sponsor
1,928 Previous Clinical Trials
2,296,941 Total Patients Enrolled
26 Trials studying COVID-19
20,210 Patients Enrolled for COVID-19
Verastem, Inc.Industry Sponsor
38 Previous Clinical Trials
2,570 Total Patients Enrolled
1 Trials studying COVID-19
47 Patients Enrolled for COVID-19
John DiPersio, M.D., Ph.D.Principal InvestigatorWashington University School of Medicine
3 Previous Clinical Trials
97 Total Patients Enrolled
1 Trials studying COVID-19
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger